pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

A2 Biotherapeutics Inc

founded 2018 · 120 employees · Agoura Hills, CA, USupdated 2mo ago

A2 Biotherapeutics is a clinical-stage cell therapy company developing logic-gated T-cell therapies for solid tumors using its proprietary Tmod platform, which pairs an activator and a blocker receptor to selectively kill tumor cells while sparing normal tissue. Lead programs target metastatic colorectal cancer and cervical cancer.

Website ↗LinkedIn ↗
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Phase 2: 2
2Phase 2
Phase 2
A-2B530
Metastatic Colorectal Cancer
Phase 2
A-2B543
Cervical Cancer

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expressionrecruitingn=474
  • —Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturingrecruitingn=200
  • phase2A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expressionrecruitingn=240
  • —A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Productsenrolling by invitationn=400
  • phase2A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expressionactive not recruitingn=160
🐶 Hiring Signal
No open roles indexed yet — view A2 Biotherapeutics Inc jobs →

News

no news has mentioned this company yet
identifiers
country
US
source
globaldata
top tags
Oncology2NSCLC1
mentioned in
0news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?